iCAD and CancerIQ have united to create an advanced breast healthcare solution. Their partnership merges iCAD’s AI-driven ProFound Breast Health Suite with CancerIQ’s precision platform, enhancing breast cancer risk prediction and personalized care plans. This collaboration aims to empower physicians and patients with accurate risk assessments, early cancer detection, and improved adherence to care. The integration of AI and lifetime risk data promises groundbreaking advancements in proactive breast health management.
iCAD, Inc., a pioneering global leader in innovative cancer-detection solutions, has joined forces with CancerIQ, a precision cancer prevention platform streamlining healthcare provider workflows and empowering high-risk patients. Together, they announced an impactful partnership aimed at developing a cutting-edge breast healthcare solution. This collaboration seeks to seamlessly integrate advanced technologies to provide comprehensive insights into cancer risks, including lifetime, genetic, and AI-detected near-term risks. The primary goal is to enable early-stage breast cancer identification, optimize treatment outcomes, and enhance patient adherence to personalized care plans.
The collaboration between iCAD and CancerIQ will amalgamate elements from iCAD’s artificial intelligence-powered ProFound Breast Health Suite with CancerIQ’s specialized software and services. This integration will result in a significantly enhanced prediction of breast cancer risk, combining AI-informed short-term risk assessments with lifetime risk evaluations. Moreover, it will introduce a unique care management and patient activation workflow designed to double adherence to payer-supported supplemental screening recommendations.
Dana Brown, the President and CEO of iCAD expressed optimism about the partnership’s potential impact, stating, “This partnership will revolutionize how patients and physicians leverage health data to schedule preventive screenings and manage breast health care effectively, ultimately saving lives. We anticipate a lasting collaboration with CancerIQ that will provide actionable and proactive care, benefiting both healthcare providers and the patients they serve.”
CancerIQ specializes in assisting healthcare providers in navigating the complexities of cancer risk assessments. Their precision platform offers personalized, evidence-based care pathways, facilitating early cancer detection and prevention. Integrated seamlessly with leading Electronic Health Record (EHR) systems, CancerIQ’s lifetime risk calculator provides comprehensive risk scores in alignment with Tyrer-Cuzick scores (7 and 8), Gail, and NCCN guidelines. When combined with iCAD’s ProFound Suite, which includes Density and AI-informed short-term risk assessments, clinicians gain a comprehensive understanding of a patient’s future breast cancer risk, coupled with the ability to detect existing breast cancer at its earliest stage.
Feyi Ayodele, co-founder and CEO of CancerIQ, emphasized the mission of making the latest innovations accessible to a wider spectrum of providers. “Aligning our platform with iCAD’s AI-enabled product suite is a crucial step in achieving our mission and delivering a more holistic solution to the market,” said Ayodele.
The partnership aims to merge CancerIQ’s lifetime risk score and genetic risk data with iCAD’s ProFound Density assessment score and ProFound Risk, offering the industry’s highest accuracy in providing one-year future risk estimates based on 2D or 3D screening mammograms. The ProFound Risk platform has demonstrated a 2.4x increase in accuracy in predicting breast cancer risk within the next year compared to traditional lifetime risk models. Additionally, iCAD’s ProFound Density Assessment, utilizing mammography images to categorize breast density, will enable the creation of personalized patient care plans inclusive of supplemental screenings and a tailored schedule.
Michelle Strong, iCAD’s Chief Operating Officer, highlighted the tremendous potential of blending their solutions, stating, “The power of combining our respective solutions will result in an unparalleled product in the market.”
This strategic partnership announcement coincides with iCAD’s participation at the Radiological Society of North America (RSNA) annual meeting in Chicago, where the company is unveiling groundbreaking research utilizing AI in breast cancer risk detection and heart disease. This serves as a testament to their commitment to advancing medical innovation and improving patient outcomes through cutting-edge technology.
The iCAD and CancerIQ partnership marks a significant leap forward in breast health care. Their integration of AI-driven technology and precise risk assessments promises a transformative impact. Through this collaboration, physicians gain powerful tools to detect breast cancer early, while patients benefit from tailored care plans and enhanced adherence to screenings. The joint endeavor emphasizes the potential of advanced technology in shaping proactive and personalized breast health management. As these innovations continue to evolve, the partnership stands at the forefront of revolutionizing breast health care globally.
